Compare NBIX & TRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | TRU |
|---|---|---|
| Founded | 1992 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 14.2B |
| IPO Year | 1996 | 2013 |
| Metric | NBIX | TRU |
|---|---|---|
| Price | $166.05 | $82.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 29 | 22 |
| Target Price | ★ $207.50 | $90.19 |
| AVG Volume (30 Days) | 1.3M | ★ 3.2M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | 41.95 | ★ 60.00 |
| EPS | ★ 5.26 | 3.59 |
| Revenue | $161,626,000.00 | ★ $4,576,300,000.00 |
| Revenue This Year | $36.46 | $12.67 |
| Revenue Next Year | $17.43 | $5.94 |
| P/E Ratio | $31.49 | ★ $21.75 |
| Revenue Growth | ★ 977.51 | 9.38 |
| 52 Week Low | $122.14 | $60.96 |
| 52 Week High | $186.12 | $89.12 |
| Indicator | NBIX | TRU |
|---|---|---|
| Relative Strength Index (RSI) | 76.47 | 58.28 |
| Support Level | $152.67 | $72.28 |
| Resistance Level | $169.57 | $81.46 |
| Average True Range (ATR) | 3.61 | 3.78 |
| MACD | 2.23 | 0.50 |
| Stochastic Oscillator | 86.44 | 67.55 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.